Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Tom MartinSaad Z UsmaniJordan M SchecterMartin VogelCarolyn C JacksonWilliam DeraedtHong TianTzu-Min YehArnob BanerjeeLida PacaudAshraf GarrettAnja HaltnerChris CameronSuzy Van SandenJoris DielsSatish ValluriImtiaz A SamjooPublished in: Current medical research and opinion (2021)
These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes, highlighting its therapeutic potential in patients with triple-class exposed RRMM.